Under the terms of the partnership, Brainomix will leverage its AI software, e-ILD technology, which has been trained to process high-resolution chest CT data in patients with interstitial lung diseases, including IPF and other conditions that cause progressive pulmonary fibrosis.

Using proprietary and patented objective imaging biomarkers and tracking changes over time, Brainomix will provide Bridge with insights and additional data on the efficacy and mechanism of action of BBT-877.